| Literature DB >> 32745110 |
Catarina Krug1, Francesca L Cavallaro1,2, Kerry L M Wong1, Antonio Gasparrini3,4,5, Adama Faye6, Caroline A Lynch1.
Abstract
BACKGROUND: Until 2011, stockouts of family planning commodities were common in Senegalese public health facilities. Recognizing the importance of addressing this problem, the Government of Senegal implemented the Informed Push Model (IPM) supply system, which involves logisticians to collect facility-level stock turnover data once a month and provide contraceptive supplies accordingly. The aims of this paper were to evaluate the impact of IPM on contraceptive availability and on stockout duration. METHODS ANDEntities:
Mesh:
Substances:
Year: 2020 PMID: 32745110 PMCID: PMC7398546 DOI: 10.1371/journal.pone.0236659
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Health facilities with all contraceptives available during the months prior and subsequent to the intervention.
The full line represents the percentage of facilities with all five contraceptives available per month, non-adjusted for sampling weights. The grey bars represent the denominator used to calculate the percentage at each month, which is the number of health facilities with data available, over a total of 103. Contraceptive products are combined pill, progesterone-only pill, injectable, implant and intrauterine device; IPM: Informed Push Model intervention; Intervention occurred at time 0.
The effect of the Informed Push Model intervention on odds of any monthly stockout for contraceptive and comparison products, in Senegalese health facilities.
| Parameter | βa | SE | ORstand (95%CI)a | ORraw (95%CI) | |||||
|---|---|---|---|---|---|---|---|---|---|
| β0 | -0.60 | 0.33 | |||||||
| β1Time | -0.01 | 0.02 | 0.617 | 0.99 | (0.96, | 1.0) | 0.99 | (0.95, | 1.0) |
| β2Intervention | -1.09 | 0.21 | <0.001 | 0.34 | (0.22, | 0.51) | 0.34 | (0.24, | 0.48) |
| β3Time*Intervention | -0.03 | 0.02 | 0.285 | 0.98 | (0.93, | 1.0) | 0.98 | (0.93, | 1.0) |
| Region-level variance | 0.00 | 0.00 | |||||||
| District-level variance | 0.00 | 0.00 | |||||||
| Facility-level variance | 4.02 | 0.99 | |||||||
| β0 | -1.10 | 0.33 | |||||||
| β1Time | 0.04 | 0.03 | 0.116 | 1.0 | (0.99, | 1.1) | 1.0 | (0.96, | 1.1) |
| β2Intervention | 0.07 | 0.42 | 0.871 | 1.1 | (0.47, | 2.4) | 1.2 | (0.56, | 2.6) |
| β3Time*Intervention | -0.04 | 0.05 | 0.354 | 0.96 | (0.88, | 1.1) | 0.97 | (0.90, | 1.1) |
| Region-level variance | 0.07 | 0.10 | |||||||
| District-level variance | 0.54 | 0.20 | |||||||
| Facility-level variance | 0.16 | 0.30 | |||||||
| β0 | -1.99 | 0.70 | |||||||
| β1Time | 0.02 | 0.04 | 0.523 | 1.0 | (0.95, | 1.1) | 1.0 | (0.94, | 1.1) |
| β2Intervention | -0.27 | 0.36 | 0.460 | 0.76 | (0.37, | 1.6) | 0.85 | (0.40, | 1.8) |
| β3Time*Intervention | 0.00 | 0.07 | 0.995 | 1.0 | (0.88, | 1.1) | 1.0 | (0.92, | 1.1) |
| Region-level variance | 0.50 | 0.41 | |||||||
| District-level variance | 0.00 | 0.00 | |||||||
| Facility-level variance | 3.23 | 1.26 | |||||||
a Accounting for clustering by facility, district, region (random effects), and zone (fixed effect) and adjusted for standardized sampling weights, which account for effective cluster size [19].
b Contraceptives were combined pill, progesterone-only pill, progesterone-only injectable, implant and intrauterine device.
β: Coefficient; SE: Standard error; ORstand: Odds ratio adjusted for standardized sampling weights; ORraw: Odds ratio obtained using logistic models accounting for clustering by facility, district, region (random effects), and zone (fixed effect) adjusted for ‘raw’ sampling weights; CI: Confidence Interval for the respective OR; n: number of facility-month observations used in the model; β0: Intercept or baseline OR; β1Time: Pre-intervention slope or secular trend per month; β2Intervention: Change in level after intervention or immediate effect; β3Time*Intervention: Post-intervention slope or gradual effect, per month.
Fig 2Duration of stockout events per contraceptive product pre- and post-intervention.
103 Senegalese health facilities; Distribution non-adjusted for sampling weights; Contraceptive product (n before, n after): injectable (92, 5), IUD (intrauterine device; 17, 8), Implant (57, 14), CPill (combined pill; 120, 13), PPill (progesterone-only pill; 49, 4), Comparison I (amoxicillin syrup; 121, 216), Comparison II (artemisinin-based combination therapy for babies; 11, 16); Intervention: Informed Push Model; Outliers > 300 d were removed (n = 3 before and n = 4 after the intervention); Very long (> 100 days) stockout durations are probably the result from missing data for several months after a stockout.
Effect of the Informed Push Model intervention on stockout duration for contraceptive and comparison products in Senegalese health facilities.
| Parameter | Level | β | SE | IRRstand (95%CI) | IRRraw (95%CI) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| β0Intercept | 3.16 | 0.12 | ||||||||
| β1Intervention | 0.52 | 0.80 | 0.518 | 1.7 | (0.35, | 8.0) | 1.5 | (0.26, | 8.1) | |
| β2Product | Injectables | Ref | ||||||||
| Intrauterine device | 1.40 | 0.34 | <0.001 | 4.1 | (2.1, | 7.9) | 4.2 | (2.1, | 8.3) | |
| Implant | 0.15 | 0.20 | 0.455 | 1.2 | (0.79, | 1.7) | 1.1 | (0.8, | 1.5) | |
| Combined pill | -0.02 | 0.24 | 0.938 | 0.98 | (0.61, | 1.6) | 0.90 | (0.55, | 1.5) | |
| Progesterone-only pill | 0.49 | 0.31 | 0.108 | 1.6 | (0.9, | 3.0) | 1.7 | (1.0, | 2.9) | |
| β3Intervention*Product | 0*Injectables | Ref | ||||||||
| 1*Intrauterine device | -2.64 | 0.93 | 0.005 | 0.07 | (0.01, | 0.45) | 0.08 | (0.01, | 0.63) | |
| 1*Implant | -0.90 | 0.41 | 0.027 | 0.41 | (0.18, | 0.91) | 0.48 | (0.19, | 1.2) | |
| 1*Combined pill | -0.75 | 0.42 | 0.070 | 0.47 | (0.21, | 1.1) | 0.55 | (0.24, | 1.3) | |
| 1*Progesterone-only pill | -0.07 | 0.57 | 0.906 | 0.93 | (0.31, | 2.9) | 1.1 | (0.28, | 3.9) | |
| Region-level variance | 0.00 | 0.00 | ||||||||
| District-level variance | 0.00 | 0.00 | ||||||||
| Facility-level variance | 3.88 | 1.15 | ||||||||
| β0Intercept | 3.16 | 0.09 | ||||||||
| β1Intervention | 0.07 | 0.18 | 0.679 | 1.1 | (0.76, | 1.5) | 1.0 | (0.72, | 1.5) | |
| Region-level variance | 0.00 | 0.00 | ||||||||
| District-level variance | 0.00 | 0.00 | ||||||||
| Facility-level variance | 0.23 | 0.13 | ||||||||
| β0Intercept | 4.46 | 0.45 | ||||||||
| β1Intervention | 0.32 | 0.43 | 0.457 | 1.4 | (0.59, | 3.2) | 1.6 | (0.61, | 4.0) | |
| Region-level variance | 0.02 | 0.21 | ||||||||
| District-level variance | 0.00 | 0.00 | ||||||||
| Facility-level variance | 0.62 | 0.26 | ||||||||
a Accounting for clustering by facility, district, region (random effects), and zone (fixed effect) and adjusted for standardized sampling weights, which account for effective cluster size [19].
b Contraceptive products were combined pill, progesterone-only pill, progesterone-only injectable, implant and intrauterine device.
β: Coefficient; SE: Standard error; IRRstand: Incidence rate ratio adjusted for standardized sampling weights; IRRraw: Incidence rate ratio accounting for clustering by facility, district, region (random effects), and zone (fixed effect) and adjusted for ‘raw’ sampling weights; CI: Confidence Interval for the respective incidence rate ratio; n: number of stockout events used in the model; Ref: reference level; 0: Time pre-intervention; 1: Time post-intervention.